Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies

Overview

Journal Front Pharmacol

Date 2022 Mar 10

PMID 35264951

Authors

Rajeev K Singla

Sahar Behzad

Johra Khan

Christos Tsagkaris

Rupesh K Gautam

Rajat Goyal

Hitesh Chopra

Bairong Shen

Affiliations

Soon will be listed here.

Abstract

Endometrial cancer (EC) is the sixth most prevalent type of cancer among women. Kinases, enzymes mediating the transfer of adenosine triphosphate (ATP) in several signaling pathways, play a significant role in carcinogenesis and cancer cells' survival and proliferation. Cyclin-dependent kinases (CDKs) are involved in EC pathogenesis; therefore, CDK inhibitors (CDKin) have a noteworthy therapeutic potential in this type of cancer, particularly in EC type 1. Natural compounds have been used for decades in the treatment of cancer serving as a source of anticancer bioactive molecules. Many phenolic and non-phenolic natural compounds covering flavonoids, stilbenoids, coumarins, biphenyl compounds, alkaloids, glycosides, terpenes, and terpenoids have shown moderate to high effectiveness against CDKin-mediated carcinogenic signaling pathways (PI3K, ERK1/2, Akt, ATM, mTOR, TP53). Pharmaceutical regimens based on two natural compounds, trabectedin and ixabepilone, have been investigated in humans showing short and midterm efficacy as second-line treatments in phase II clinical trials. The purpose of this review is twofold: the authors first provide an overview of the involvement of kinases and kinase inhibitors in the pathogenesis and treatment of EC and then discuss the existing evidence about natural products' derived kinase inhibitors in the management of the disease and outline relevant future research.

Citing Articles

Epigallocatechin-3-gallate therapeutic potential in human diseases: molecular mechanisms and clinical studies.

Alam M, Gulzar M, Akhtar M, Rashid S, Zulfareen , Tanuja Mol Biomed. 2024; 5(1):73.

PMID: 39725830 PMC: 11671467. DOI: 10.1186/s43556-024-00240-9.

Investigation into the Neuroprotective and Therapeutic Potential of Plant-Derived Chk2 Inhibitors.

Kisielewska M, Filipski M, Sebastianka K, Karas D, Molik K, Choromanska A Int J Mol Sci. 2024; 25(14).

PMID: 39062967 PMC: 11277127. DOI: 10.3390/ijms25147725.

Natural products in the management of neurodegenerative diseases.

Goyal R, Mittal P, Gautam R, Kamal M, Perveen A, Garg V Nutr Metab (Lond). 2024; 21(1):26.

PMID: 38755627 PMC: 11100221. DOI: 10.1186/s12986-024-00800-4.

Uncovering a novel DNA repair-related radiosensitivity model for evaluation of radiotherapy susceptibility in uterine corpus endometrial cancer.

Yang H, Qiu Y, Chen J, Lai J Heliyon. 2024; 10(8):e29401.

PMID: 38628740 PMC: 11019234. DOI: 10.1016/j.heliyon.2024.e29401.

(L.) Mill. - anticancer properties and phytochemicals: current trends and future perspectives.

Wang J, Rani N, Jakhar S, Redhu R, Kumar S, Kumar S Front Plant Sci. 2023; 14:1236123.

PMID: 37860248 PMC: 10582960. DOI: 10.3389/fpls.2023.1236123.

References

Zhang X, Kan H, Liu Y, Ding W . Plumbagin induces Ishikawa cell cycle arrest, autophagy, and apoptosis via the PI3K/Akt signaling pathway in endometrial cancer. Food Chem Toxicol. 2020; 148:111957. DOI: 10.1016/j.fct.2020.111957. View

Gouveia D, Guimaraes A, Santos W, Quintans-Junior L . Natural products as a perspective for cancer pain management: A systematic review. Phytomedicine. 2019; 58:152766. DOI: 10.1016/j.phymed.2018.11.026. View

Schwartz P, Murray B . Protein kinase biochemistry and drug discovery. Bioorg Chem. 2011; 39(5-6):192-210. DOI: 10.1016/j.bioorg.2011.07.004. View

Jenwitheesuk A, Boontem P, Wongchitrat P, Tocharus J, Mukda S, Govitrapong P . Melatonin regulates the aging mouse hippocampal homeostasis via the sirtuin1-FOXO1 pathway. EXCLI J. 2017; 16:340-353. PMC: 5427465. DOI: 10.17179/excli2016-852. View

Leonarduzzi G, Testa G, Sottero B, Gamba P, Poli G . Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr Med Chem. 2009; 17(1):74-95. DOI: 10.2174/092986710789957760. View

Jiang R, Su G, Chen X, Chen S, Li Q, Xie B . Esculetin inhibits endometrial cancer proliferation and promotes apoptosis via hnRNPA1 to downregulate BCLXL and XIAP. Cancer Lett. 2021; 521:308-321. DOI: 10.1016/j.canlet.2021.08.039. View

Chopra H, Dey P, Das D, Bhattacharya T, Shah M, Mubin S . Curcumin Nanoparticles as Promising Therapeutic Agents for Drug Targets. Molecules. 2021; 26(16). PMC: 8402133. DOI: 10.3390/molecules26164998. View

Singla R . Secondary Metabolites as Treatment of Choice for Metabolic Disorders and Infectious Diseases and their Metabolic Profiling: Part 1. Curr Drug Metab. 2020; 21(7):480-481. DOI: 10.2174/138920022107200925101631. View

Zhang F, Zhang Y, Sun Y, Ma R, Thakur K, Zhang J . Asparanin A from L. Induces G0/G1 Cell Cycle Arrest and Apoptosis in Human Endometrial Carcinoma Ishikawa Cells via Mitochondrial and PI3K/AKT Signaling Pathways. J Agric Food Chem. 2019; 68(1):213-224. DOI: 10.1021/acs.jafc.9b07103. View

10.

Cheng P, Ma J, Zheng X, Zhou C, Chen X . Bioinformatic profiling identifies prognosis-related genes in the immune microenvironment of endometrial carcinoma. Sci Rep. 2021; 11(1):12608. PMC: 8206132. DOI: 10.1038/s41598-021-92091-5. View

11.

Jorda R, Hendrychova D, Voller J, Reznickova E, Gucky T, Krystof V . How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?. J Med Chem. 2018; 61(20):9105-9120. DOI: 10.1021/acs.jmedchem.8b00049. View

12.

Han Q, Wang X, Cai S, Liu X, Zhang Y, Yang L . Quercetin nanoparticles with enhanced bioavailability as multifunctional agents toward amyloid induced neurotoxicity. J Mater Chem B. 2020; 6(9):1387-1393. DOI: 10.1039/c7tb03053c. View

13.

Gupta T, Singh J, Kaur S, Sandhu S, Singh G, Kaur I . Enhancing Bioavailability and Stability of Curcumin Using Solid Lipid Nanoparticles (CLEN): A Covenant for Its Effectiveness. Front Bioeng Biotechnol. 2020; 8:879. PMC: 7593682. DOI: 10.3389/fbioe.2020.00879. View

14.

Trynda-Lemiesz L . Paclitaxel-HSA interaction. Binding sites on HSA molecule. Bioorg Med Chem. 2004; 12(12):3269-75. DOI: 10.1016/j.bmc.2004.03.073. View

15.

Li D, Zhang J, Zhao X . Mechanisms and Molecular Targets of Artemisinin in Cancer Treatment. Cancer Invest. 2021; 39(8):675-684. DOI: 10.1080/07357907.2021.1954190. View

16.

Pourhanifeh M, Darvish M, Tabatabaeian J, Fard M, Mottaghi R, Azadchehr M . Therapeutic role of curcumin and its novel formulations in gynecological cancers. J Ovarian Res. 2020; 13(1):130. PMC: 7643381. DOI: 10.1186/s13048-020-00731-7. View

17.

Nageen B, Sarfraz I, Rasul A, Hussain G, Rukhsar F, Irshad S . Eupatilin: a natural pharmacologically active flavone compound with its wide range applications. J Asian Nat Prod Res. 2018; 22(1):1-16. DOI: 10.1080/10286020.2018.1492565. View

18.

Mutter G, Lin M, Fitzgerald J, Kum J, Baak J, Lees J . Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000; 92(11):924-30. DOI: 10.1093/jnci/92.11.924. View

19.

Suresh Managuli R, Raut S, Reddy M, Mutalik S . Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs. Expert Opin Drug Deliv. 2018; 15(8):787-804. DOI: 10.1080/17425247.2018.1503249. View

20.

Lax S, Kendall B, Tashiro H, Slebos R, Hedrick L . The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000; 88(4):814-24. View